DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Neuropathic Pain

Interventions: Drug: pregabalin sustained release tablet
Drug: pregabalin immediate release capsule

First Posted Date: 2022-11-22

Last Posted Date: 2023-10-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 130

Registration Number: NCT05624853

Locations: 🇰🇷
Dankook University Hospital, Cheonan, Chungcheongnam-do, Korea, Republic of
🇰🇷
Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷
Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Korea, Republic of

and more 5 locations

A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases

Phase 1

Completed

Conditions: Atopic Healthy Subjects
Adult Subjects With Allergic Diseases

Interventions: Drug: Placebo
Drug: YH35324
Drug: Omalizumab

First Posted Date: 2022-10-03

Last Posted Date: 2025-01-24

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 46

Registration Number: NCT05564221

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Nowon Eulji Medical Center, Seoul, Korea, Republic of
🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

and more 6 locations

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Phase 1

Recruiting

Conditions: HER2-Positive Solid Tumor

Interventions: Drug: YH32367

First Posted Date: 2022-09-01

Last Posted Date: 2025-04-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 137

Registration Number: NCT05523947

Locations: 🇦🇺
Southern Oncology Clinical Research Unit, Adelaide, Australia
🇦🇺
Austin Health, Melbourne, Australia
🇦🇺
Breast Cancer Research Centre - WA, Perth, Australia

and more 8 locations

BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: YHP1807 Tab. 2.5mg
Drug: YHR1901 Tab. 2.5mg

First Posted Date: 2022-06-14

Last Posted Date: 2022-06-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 34

Registration Number: NCT05418803

Locations: 🇰🇷
Jeonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of

Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Adult Volunteers

Interventions: Drug: Lazertinib(G001)
Drug: Lazertinib(G002)

First Posted Date: 2021-12-17

Last Posted Date: 2024-12-11

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 38

Registration Number: NCT05162274

Locations: 🇰🇷
Seoul National University Hospital Clinical Trial Center, Seoul, Korea, Republic of

A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases

Phase 1

Completed

Conditions: Atopic Healthy Subjects
Adult Subjects with Mild Allergic Diseases

Interventions: Drug: YH35324
Drug: Placebo
Drug: Omalizumab

First Posted Date: 2021-09-29

Last Posted Date: 2024-12-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 68

Registration Number: NCT05061524

Locations: 🇰🇷
Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University Health System, Sinchon-dong, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Gumi, Sungnamsi, Korea, Republic of

and more 1 locations

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer
Renal Impairments

Interventions: Drug: YHD1119 75mg

First Posted Date: 2021-08-19

Last Posted Date: 2022-06-30

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 16

Registration Number: NCT05012436

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

Phase 4

Completed

Conditions: Diabetic Peripheral Neuropathy

Interventions: Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg
Drug: Pregabalin 150mg
Drug: Alpha-Lipoic Acid 480mg

First Posted Date: 2021-04-15

Last Posted Date: 2025-04-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 151

Registration Number: NCT04846673

Locations: 🇰🇷
Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, Incheon ST. Mary's Hospital, Incheon, Korea, Republic of
🇰🇷
Jeju National University College of Medicine, Jeju, Korea, Republic of

and more 11 locations

Early Access Program of Lazertinib in Republic of Korea

Conditions: Lung Cancer

First Posted Date: 2021-04-02

Last Posted Date: 2022-03-03

Lead Sponsor: Yuhan Corporation

Registration Number: NCT04829422

Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: YHP1906
Drug: YHR1902

First Posted Date: 2020-03-20

Last Posted Date: 2020-05-26

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 30

Registration Number: NCT04316065

Locations: 🇰🇷
Metro Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy